(CLDX) Celldex Therapeutics - Overview
Stock: Monoclonal Antibody, Bispecific Antibody, KIT Inhibitor, Inflammatory Diseases
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 58.5% |
| Relative Tail Risk | -7.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -17.69 |
| Character TTM | |
|---|---|
| Beta | 1.094 |
| Beta Downside | 0.718 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.84% |
| CAGR/Max DD | -0.26 |
Description: CLDX Celldex Therapeutics January 15, 2026
Celldex Therapeutics (NASDAQ:CLDX) is a U.S.-based biopharma focused on antibody-based therapies for severe inflammatory, allergic, and autoimmune conditions that lack adequate treatment options. Its pipeline centers on two late-stage candidates: Barzolvolimab (CDX-0159), a KIT-targeting monoclonal antibody being evaluated in chronic urticaria, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific antibody that simultaneously blocks thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem-cell factor (SCF) inhibition.
Key operational metrics (as of Q3 2024 filing) show a cash runway of roughly $45 million, supporting R&D through at least 2025 under current burn-rate assumptions. The company recently secured a $30 million milestone-linked partnership with Roche to co-develop CDX-0159, which should de-risk funding and accelerate clinical timelines. Market analysis estimates the global chronic urticaria market at > $3 billion, with a CAGR of ~ 7 %-a potential revenue tailwind if Barzolvolimab achieves Phase III success.
Sector-wide drivers include sustained venture capital inflows into immunology biotech (U.S. biotech IPO activity up 12 % YoY) and FDA’s increasing use of Fast Track and Breakthrough Therapy designations for novel anti-inflammatory biologics, which can shorten time-to-market and reduce regulatory risk.
For a deeper, data-driven view of CLDX’s valuation dynamics, a quick look at ValueRay’s analyst dashboard may uncover additional quantitative insights worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -224.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -8.76 > 1.0 |
| NWC/Revenue: 21.5k% < 20% (prev 7485 %; Δ 14.0k% < -1%) |
| CFO/TA -0.28 > 3% & CFO -179.5m > Net Income -224.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.4m) vs 12m ago 0.19% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.35% > 50% (prev 1.21%; Δ -0.86% > 0%) |
| Interest Coverage Ratio: -8.08 > 6 (EBITDA TTM -252.9m / Interest Expense TTM -31.7m) |
Altman Z'' -15.00
| A: 0.86 (Total Current Assets 604.3m - Total Current Liabilities 46.5m) / Total Assets 648.4m |
| B: -2.67 (Retained Earnings -1.73b / Total Assets 648.4m) |
| C: -0.35 (EBIT TTM -256.2m / Avg Total Assets 735.8m) |
| D: -34.52 (Book Value of Equity -1.73b / Total Liabilities 50.1m) |
| Altman-Z'' Score: -41.66 = D |
Beneish M -3.97
| DSRI: 0.41 (Receivables 90.0k/852.0k, Revenue 2.60m/9.98m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.26 (AQ_t 0.06 / AQ_t-1 0.04) |
| SGI: 0.26 (Revenue 2.60m / 9.98m) |
| TATA: -0.07 (NI -224.5m - CFO -179.5m) / TA 648.4m) |
| Beneish M-Score: -3.97 (Cap -4..+1) = AAA |
What is the price of CLDX shares?
Over the past week, the price has changed by -3.41%, over one month by -9.59%, over three months by +2.15% and over the past year by +2.02%.
Is CLDX a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.4 | 124.6% |
| Analysts Target Price | 53.4 | 124.6% |
| ValueRay Target Price | 22.4 | -5.8% |
CLDX Fundamental Data Overview February 03, 2026
P/B = 2.7419
Revenue TTM = 2.60m USD
EBIT TTM = -256.2m USD
EBITDA TTM = -252.9m USD
Long Term Debt = 2.62m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.55m USD (from shortTermDebt, last quarter)
Debt = 2.62m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.05b USD (1.63b + Debt 2.62m - CCE 583.2m)
Interest Coverage Ratio = -8.08 (Ebit TTM -256.2m / Interest Expense TTM -31.7m)
EV/FCF = -5.80x (Enterprise Value 1.05b / FCF TTM -181.7m)
FCF Yield = -17.24% (FCF TTM -181.7m / Enterprise Value 1.05b)
FCF Margin = -6987 % (FCF TTM -181.7m / Revenue TTM 2.60m)
Net Margin = -8636 % (Net Income TTM -224.5m / Revenue TTM 2.60m)
Gross Margin = unknown ((Revenue TTM 2.60m - Cost of Revenue TTM 63.8m) / Revenue TTM)
Tobins Q-Ratio = 1.63 (Enterprise Value 1.05b / Total Assets 648.4m)
Interest Expense / Debt = 118.7% (Interest Expense 3.11m / Debt 2.62m)
Taxrate = 21.0% (US default 21%)
NOPAT = -202.4m (EBIT -256.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.01 (Total Current Assets 604.3m / Total Current Liabilities 46.5m)
Debt / Equity = 0.00 (Debt 2.62m / totalStockholderEquity, last quarter 598.4m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -33.4m / EBITDA -252.9m)
Debt / FCF = 0.18 (negative FCF - burning cash) (Net Debt -33.4m / FCF TTM -181.7m)
Total Stockholder Equity = 675.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.51% (Net Income -224.5m / Total Assets 648.4m)
RoE = -33.22% (Net Income TTM -224.5m / Total Stockholder Equity 675.9m)
RoCE = -37.76% (EBIT -256.2m / Capital Employed (Equity 675.9m + L.T.Debt 2.62m))
RoIC = -29.95% (negative operating profit) (NOPAT -202.4m / Invested Capital 675.9m)
WACC = 9.93% (E(1.63b)/V(1.64b) * Re(9.95%) + (debt cost/tax rate unavailable))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.99%
Fair Price DCF = unknown (Cash Flow -181.7m)
EPS Correlation: -4.07 | EPS CAGR: 17.67% | SUE: 4.0 | # QB: 1
Revenue Correlation: 22.45 | Revenue CAGR: -37.10% | SUE: -0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.06 | Chg30d=-0.004 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-4.42 | Chg30d=-0.010 | Revisions Net=-3 | Growth EPS=-23.1% | Growth Revenue=+29.7%